<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1607">
  <stage>Registered</stage>
  <submitdate>27/06/2007</submitdate>
  <approvaldate>27/06/2007</approvaldate>
  <nctid>NCT00494442</nctid>
  <trial_identification>
    <studytitle>Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer</studytitle>
    <scientifictitle>A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer</scientifictitle>
    <utrn />
    <trialacronym>ICEBERG 2</trialacronym>
    <secondaryid>D0810C00009</secondaryid>
    <secondaryid>KU36-58</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ovarian Neoplasm</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - KU-0059436 (AZD2281)(PARP inhibitor)
Treatment: drugs - KU-0059436 (AZD2281)(PARP inhibitor)

Experimental: KU-0059436 (AZD2281) 100 mg BID - 

Experimental: KU-0059436 (AZD2281) 400 mg BID - 


Treatment: drugs: KU-0059436 (AZD2281)(PARP inhibitor)
oral

Treatment: drugs: KU-0059436 (AZD2281)(PARP inhibitor)
oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST) - Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease from baseline in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</outcome>
      <timepoint>Baseline, every 8 also at study termination or initiation of confounding anti-cancer therapy.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Benefit (CB) - Clinical Benefit (CB) is defined as the percentage of patients with a RECIST tumour response of confirmed complete response, partial response or stable disease for =8 weeks)</outcome>
      <timepoint>End of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response - Duration of response to olaparib</outcome>
      <timepoint>End of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best Percentage Change in Tumour Size - The best % change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).</outcome>
      <timepoint>End of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-Free Survival (PFS) - Progression-Free Survival (PFS) is defined as the time from first dose to the earlier date of radiologic progression (as per RECIST criteria) or death by any cause in the absence of objective progression.</outcome>
      <timepoint>End of study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Advanced ovarian cancer with positive BRCA1 or BRCA2 status

          -  Failed at least one prior chemotherapy

          -  In investigators opinion, no curative standard therapy exists

          -  Measurable disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>130</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Brain metastases

          -  Less than 28 days since last treatment used to treat the disease

          -  Considered a poor medical risk due to a serious uncontrolled disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>11/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>57</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>20/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Melbourne, Parkville</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <hospital>Research Site - Randwick</hospital>
    <postcode>VIC 3050 - Melbourne, Parkville</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>2031 - Randwick</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>KÃ¶ln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Hospitalet deLlobregat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>KuDOS Pharmaceuticals Limited</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in
      treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for
      whom no curative therapeutic option exists.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00494442</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>James Carmichael, BSc MBChB MD FRCP</name>
      <address>KuDOS Pharmaceuticals Limited</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>